NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Biomerica, Inc. (BMRA) Stock Analysis

Biomerica, Inc. (BMRA) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BMRA

$1.71

−$0.01 (−0.51%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BMRA with… →

BMRA Key Statistics

As of Oct 21, 2026
Trading
Open
$1.69
Previous Close
$1.72
Day's Range
1.60–1.71
52-Week Range
1.45–3.21
Volume
7.54K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.38
Valuation
Market Cap
$8.62M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
4.81
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.94
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.30
Financials (FY)
Revenue (FY)
$5.31M−1.92%
Net Income (FY)
−$4.97M
Profit marginThe share of revenue left as profit after all costs and taxes.
−84.77%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.60M
1-Year Return
−46.56%
Dividend and dates
Avg Volume
71.21K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BMRA closed at $1.71, −46.56% over 1 year.

Biomerica, Inc. (BMRA) has a market capitalization of $8.62M.

In fiscal 2024, BMRA reported revenue of $5.31M.

BMRA Stock Return by Calendar Year

Biomerica, Inc. (BMRA) 10-year return: what $10,000 became

1 year
$10,000 $5,344
−46.56%
5 years
$10,000 $411
−95.89%
10 years
$10,000 $792
−92.08%

If you had invested $10,000 in Biomerica, Inc. (BMRA) 10 years ago, at the close on October 21, 2016, it would have been worth $792 at the close on October 21, 2026: −92.08% in total, −22.40% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−32.14%
2025+5.00%
2024−76.00%
2023−62.69%
2022−13.88%
2021−21.89%
2020+64.90%
2019+77.65%
2018−54.55%
2017+62.61%
2016 (partial year)−12.55%

As of October 21, 2026.

BMRA Revenue and Earnings by Fiscal Year

FY ends May
Fiscal yearRevenueNet incomeNet margin
2024$5.31M−$4.97M−93.6%
2023$5.42M−$5.98M−110.4%
2022$5.34M−$7.14M−133.7%
2021$18.87M−$4.53M−24.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$5.31M$498.00K−$5.14M−$4.97M−93.6%
2023$5.42M$611.00K−$6.37M−$5.98M−110.4%
2022$5.34M$446.00K−$7.22M−$7.14M−133.7%
2021$18.87M$2.98M−$4.53M−$4.53M−24.0%

Annual figures as reported, in the company's reporting currency. As of May 31, 2025.

BMRA Valuation vs Medical Devices Median

Median of 145 stocks
MetricBMRAMedical Devices medianvs median
P/S ratio1.942.5323% below
Profit margin−84.77%−14.78%70.0 pts below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Biomerica, Inc. (BMRA) is capitalised at $8.62M on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 50 employees.

The 52-week range on file runs from $1.45 to $3.21. The most recent close on file for BMRA is $1.71, dated October 21, 2026. That is −$0.01 (−0.51%) against the previous close. The latest close sits 17.93% above that 52-week low.

Financial Health

Fiscal 2024 revenue came to $5.31M. Against the prior fiscal year total of $5.42M, that is a change of −1.92%. The same year closed with a net loss of $4.97M. The reported profit margin is −84.77%. That is 70 percentage points below the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to −1.3.

Across the 4 fiscal years on file, revenue moves from $18.87M in 2021 to $5.31M in 2024. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 4.81. The price-to-sales ratio is 1.94. On price-to-sales that is 23.45% below the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

Beta against the wider market is reported at 0.38. Daily returns over the trailing 10 years annualize to a volatility of 139.83%. The trailing one-year total return is −46.56%. Across 10 years the annualized return works out at −22.40%.

Growth & Income

No dividend is on file for BMRA.

Across the complete calendar years on file, 2019 returned +77.65% and 2024 returned −76.00%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the total return is −32.14%.

Peer Comparison

Biomerica, Inc. (BMRA) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Biomerica, Inc. BMRA $8.62M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Biomerica, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Biomerica, Inc.

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways. Further, it is involved in the development and optimization of immunoassays, enzyme-linked immunosorbent assays, rapid diagnostic tests, and related diagnostic technologies; and research, development, commercialization of diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. Additionally, the company offers EZ detect colon disease home test; Aware Breast Self-Exam product; and hp+detect, a diagnostic test designed to detect Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Visit website →